Preview: Senseonics Holdings's Earnings
Senseonics Holdings (AMEX:SENS) is preparing to release its quarterly earnings on Monday, 2026-03-02. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Senseonics Holdings to report an earnings per share (EPS) of $-0.43.
Senseonics Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Past Earnings Performance
During the last quarter, the company reported an EPS missed by $0.06, leading to a 7.58% drop in the share price on the subsequent day.
Here's a look at Senseonics Holdings's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.37 | -0.40 | -0.40 | -0.60 |
| EPS Actual | -0.43 | -0.40 | -0.40 | -0.60 |
| Price Change % | -7.58 | -4.87 | -15.17 | -19.31 |
Tracking Senseonics Holdings's Stock Performance
Shares of Senseonics Holdings were trading at $8.35 as of February 26. Over the last 52-week period, shares are down 52.24%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Unveiling the Story Behind Senseonics Holdings
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
Unraveling the Financial Story of Senseonics Holdings
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Senseonics Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 89.89% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Senseonics Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -241.26% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Senseonics Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -22.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -13.46%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Senseonics Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
To track all earnings releases for Senseonics Holdings visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.